2nd Annual Gene Therapy Immunogenicity

FDA’s risk based guidance for managing IG is focusing on the use of modeling & simulation for proteins, vaccines and new modalities, This immunogenicity modeling technology is being applied to address the unmet needs emerging from advanced therapies, specifically gene therapy, A case study demonstrating the use of this approach for dose optimization for gene therapy will be shared